Save Product
Product Details
Materials Provided
IDComponentsSizeEP165-C01Human TNF-alpha coated Plate1 plateEP165-C02Anti-TNF-alpha Neutralizing Antibody10 μgEP165-C03HRP-Human TNFR110 μgEP165-C0420xWashing Buffer50 mLEP165-C051×Dilution Buffer50 mLEP165-C06Substrate Solution12 mLEP165-C07Stop Solution7 mLProduct Overview
TNF-alpha : TNFR1[HRP] Inhibitor Screening ELISA Kit-Pre coated plate is based on a competition-ELISA method, is used to screening for inhibitors of human TNF-alpha binding to human TNFR1. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human TNF-alpha binding to human TNFR1.
Reconstitution
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage
Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Typical Data
Please refer to DS document for the assay protocol.
INHIBITION OF TNF-alpha: TNFR1[HRP] BINDING BY ANTI- TNF-alpha NEUTRALIZING ANTIBODY
Serial dilutions of ANTI- TNF-alpha Neutralizing Antibody (Catalog # EP165-C02) (1:1 serial dilution, from 5μg/mL to 0.002441406 μg/mL) was added into TNF-alpha: TNFR1[HRP] binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Customer Reviews Writing Reviews
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor α
- Category：
- Approved Drugs：
68 Details
- Drugs in Clinical Trials：
74 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
